

**Form 51-102F3  
Material Change Report**

**Item 1 Name and Address of Company**

Veritas Pharma Inc.  
(the "Company")  
101 - 2386 East Mall  
Vancouver, BC V6T 1Z3

**Item 2 Date of Material Change**

July 12, 2016 updated October 5, 2016

**Item 3 News Release**

None

**Item 4 Summary of Material Change**

The Company entered into an Amended Share Purchase Agreement with Cannevert Therapeutics Ltd. ("CTL") dated July 12, 2016, effective May 31, 2016. The effect of this amendment was to revise the payment schedule. Instead of making the scheduled May 31, 2016, it was agreed that the Company would pay CTL \$100,000 on July 15, 2016 and \$150,000 on July 31, 2016. Quarterly installments of \$250,000 are due on November 1, 2016; February 1, 2017 and May 1, 2017. This filing incorporates a copy of the Amended Share Purchase Agreement between Cannevert Therapeutics Ltd. ("CTL") dated July 12, 2016, effective May 31, 2016.

**Item 5 Full Description of Material Change**

**5.1 Full Description of Material Change**

None

**5.2 Disclosure for Restructuring Transactions**

N/A

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

N/A

**Item 7 Omitted Information**

N/A

**Item 8 Executive Officer**

Dr. Lui Franciosi, CEO and Director, (778) 968-6260  
Email: [ir@veritaspharmainc.com](mailto:ir@veritaspharmainc.com)

**Item 9 Date of Report**

The foregoing accurately discloses the material change referred to herein.

DATED at Vancouver, British Columbia, this 12th day of August, 2016.

**VERITAS PHARMA INC.**

*"Dr. Luigi Franciosi"*

Per: Dr. Luigi Franciosi